Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Visit LucidCGT ↗ · See the full LucidQuest ecosystem
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
October 15, 2026
UEG Week 2026 Preview: Competitive Shifts in Gastroenterology
October 15, 2026
AstraZeneca–HUTCHMED FDA Filing | Lucid Diligence Brief
October 14, 2026
Women’s Health Strategic Roundup: Earlier Intervention | Sep 08 – Oct 13, 2026
October 13, 2026
AI in Healthcare and Digital Health Strategic Roundup: Clinical Adoption | Sep 12 – Oct 12, 2026
October 10, 2026
ECNP 2026 Preview: Emerging Psychiatric Therapies and Competitive Trends
October 9, 2026
HFSA 2026 Preview: Key Heart Failure Treatment Trends And Pipeline
October 9, 2026
Respiratory Strategic Roundup: Earlier Intervention | Sep 4–Oct 7, 2026
October 7, 2026
Cell and Gene Therapy Strategic Roundup | Sep 1 – Oct 6, 2026
October 7, 2026
Strategy Wargaming: What FDA’s Volixibat Signal Means for Ipsen
October 6, 2026
Obesity Strategic Roundup: Beyond GLP-1 Efficacy | Sep 1 – Oct 4 , 2026
October 6, 2026